实体瘤导致 90% 的癌症，并且仍然是死亡的主要原因。然而，由于复杂的肿瘤微环境和耐药性，实体瘤的治疗面临着巨大的挑战，导致治疗靶向性不足和严重的副作用。手术、放疗、化疗虽然是治疗实体瘤的有效方法，但会导致器官功能障碍，影响患者预后。因此，提高实体瘤的治疗精度和器官修复能力势在必行。间充质干细胞胞外囊泡（MSC-EVs）作为实体瘤治疗新剂具有广阔的应用前景。首先，MSC-EVs是MSCs的衍生物。它具有通过诱导损伤后存活细胞去分化来促进组织再生的功能。此外，MSC-EV在安全性、稳定性和渗透性方面具有独特的优势，使其成为一种有前途的实体瘤治疗细胞外治疗方式。最后，MSC-EV 能够通过工程策略增强治疗效果。综上所述，本次评审以MSC-EV为对象。然后我们讨论使用 MSC-EV 抑制实体瘤的最新进展和工程策略。本综述旨在激励研究人员设计一种有效治疗实体瘤的新方法。© 作者。

Solid tumors cause 90% of cancers and remain the primary cause of mortality. However, treating solid tumors presents significant challenges due to the complex tumor microenvironment and drug resistance, leading to inadequate treatment targeting and severe side effects. Surgery, radiotherapy, and chemotherapy Although it is an effective method for the treatment of solid tumors, it can lead to organ dysfunction and affect patient prognosis. Therefore, it is imperative to improve treatment precision and organ repair capabilities to manage solid tumors. Mesenchymal stem cell extracellular vesicles (MSC-EVs) have wide application prospects as a new agent for solid tumor therapy. Firstly, MSC-EVs is a derivative of MSCs. It has the function of promoting tissue regeneration by inducing dedifferentiation in surviving cells after injury. Additionally, MSC-EVs offer unique advantages in terms of safety, stability and penetrability, making them a promising extracellular therapeutic modality for solid tumor treatment. Finally, MSC-EVs are able to enhance therapeutic efficacy through engineering strategies. To sum up, this review takes MSC-EVs as its object. And then we discuss recent advancements and engineering strategies in the use of MSC-EVs for soid tumor suppression. This review aims to inspire researchers to devise a new method for effectively treat solid tumors.© The author(s).